New drug combo aims to shrink aggressive prostate cancer before surgery
NCT ID NCT07476677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called darolutamide, with or without hormone therapy (ADT), given before surgery for high-risk localized prostate cancer. Sixty men will be split into two groups: one gets darolutamide alone, the other gets darolutamide plus ADT for 3-6 months before robotic surgery. The goal is to see if the treatment reduces cancer enough to improve surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Darolutamide (a drug that blocks male hormones) with or without ADT (androgen deprivation therapy)
- What this could lead to
- If successful, this could lead to a new treatment option that shrinks high-risk prostate cancer before surgery, potentially improving outcomes.
- What could go wrong
- This is a small, early-phase study (60 people) with no results yet. The treatment may not work better than current options, and ADT can cause side effects like hot flashes and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 101205, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?